Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In Hypercholesterolaemia
Completed
- Conditions
- Hypercholesterolaemia
- Registration Number
- NCT01352897
- Lead Sponsor
- AstraZeneca
- Brief Summary
The objective of this follow-up retrospective study is to evaluate the long term efficacy and safety of rosuvastatin in reducing lipid parameters in clinical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
- Primary hypercholesterolemia
- Subjects from first rosuvastatin Registry study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients who maintain US NCEP ATP III LDL-C target goals after long-term therapy Up to 8 years
- Secondary Outcome Measures
Name Time Method LDL-cholesterol levels Up to 8 years HDL-cholesterol levels Up to 8 years Proportion of patients having raised levels of serum CK or ALT Up to 8 years
Trial Locations
- Locations (1)
Research Site
🇸🇬Singapore, Singapore